Briefing Healthy Demand Neuren Pharmaceuticals shares lift as Daybue sales hit $139m in Q1 7 May 2026
Briefing Pending Approval Acadia Pharmaceuticals plans to re-examine Rett syndrome treatment following EU setback 3 March 2026
Briefing Biotech bust Neuren Pharmaceuticals FY profit falls to $30m despite Daybue sales 27 February 2026
Briefing Trial Test Neuren Pharmaceuticals starts first clinical trial for Phelan-McDermid Syndrome 6 February 2026
Briefing Meeting Moves Neuren Pharmaceuticals slumps despite receiving FDA meeting feedback 5 February 2026
Briefing Trial and Error Neuren gains FDA feedback on Pitt Hopkins and HIE drug trial 4 February 2026
Briefing Trading Halt Neuren Pharmaceuticals enters trading halt ahead of FDA announcement 4 February 2026
Briefing Disclosure Delay Neuren says it disclosed Daybue sales projections 'without delay' after ASX aware letter 19 January 2026
Briefing Rare Remedy FDA approves oral solution for Neuren's Rett syndrome treatment 15 December 2025
Briefing Biotech Boost Neuren Pharmaceuticals reports 24% rise in quarterly royalties 6 November 2025
Briefing Biotech Boost Neuren shares rally as Macquarie opens coverage with 'outperform' rating 18 June 2025
Briefing Price drop ASX-listed pharmaceutical companies sink after Trump post on drug costs 12 May 2025
Briefing Royal Rewards Neuren posts fall in full-year profit despite rise in Daybue royalties 28 February 2025
